- Home
- SABA vs SGHT Comparison
SABA vs SGHT Comparison
Compare SABA & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABA
- SGHT
- Stock Information
- Founded
- SABA 1988
- SGHT 2011
- Country
- SABA United States
- SGHT United States
- Employees
- SABA N/A
- SGHT N/A
- Industry
- SABA
- SGHT Medical Specialities
- Sector
- SABA
- SGHT Health Care
- Exchange
- SABA Nasdaq
- SGHT Nasdaq
- Market Cap
- SABA 260.7M
- SGHT 304.4M
- IPO Year
- SABA N/A
- SGHT 2021
- Fundamental
- Price
- SABA $9.21
- SGHT $2.80
- Analyst Decision
- SABA
- SGHT Buy
- Analyst Count
- SABA 0
- SGHT 7
- Target Price
- SABA N/A
- SGHT $5.02
- AVG Volume (30 Days)
- SABA 290.0K
- SGHT 234.3K
- Earning Date
- SABA 01-01-0001
- SGHT 03-06-2025
- Dividend Yield
- SABA 12.91%
- SGHT N/A
- EPS Growth
- SABA N/A
- SGHT N/A
- EPS
- SABA N/A
- SGHT N/A
- Revenue
- SABA N/A
- SGHT $79,543,000.00
- Revenue This Year
- SABA N/A
- SGHT $1.74
- Revenue Next Year
- SABA N/A
- SGHT $4.81
- P/E Ratio
- SABA N/A
- SGHT N/A
- Revenue Growth
- SABA N/A
- SGHT N/A
- 52 Week Low
- SABA $3.64
- SGHT $2.68
- 52 Week High
- SABA $4.42
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- SABA 61.75
- SGHT 34.43
- Support Level
- SABA $9.18
- SGHT $2.69
- Resistance Level
- SABA $9.43
- SGHT $3.15
- Average True Range (ATR)
- SABA 0.16
- SGHT 0.18
- MACD
- SABA 0.02
- SGHT 0.01
- Stochastic Oscillator
- SABA 75.96
- SGHT 21.37
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.